ImmuneOncia aims to develop immuno-oncology therapeutics
to transform the standard of care in cancer treatment
- Technology
- Pipeline
Pipeline
ImmuneOncia Pipeline
| Category | Pipeline | Target | Discovery | Preclinical | Clinical Stage | Partner / Clinical Trial Institution | ||
|---|---|---|---|---|---|---|---|---|
| Phase 1 | Phase 2 | Phase 3 | ||||||
| mAb | IMC-001 | PD-L1 |
NK/T Cell Lymphoma (Phase 2) |
 |
||||
|
TMB-H Solid Tumor (Phase 2) |
|
|||||||
|
Neo-Adjuvant Study (Phase2, IIT) |
 |
|||||||
| IMC-002 | CD47 |
Solid Tumor (Phase 1b) |
 
|
|||||
| IMC-003 | LAG-3 |
|
||||||
| BsAb | IMC-201 | CD47xPD-L1 |
|
 |
||||
| IOH-006 | CD47xTarget A |
|
||||||
| mAb-Cyt | IOH-005 | LAG-3xCytokine |
|
|||||
H.Q: 25, Tapsil-ro 35beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 17084, Republic of Korea
R&D Center: Suite 6F, Genexine ProGen Bio Innovation Park, 172, Magokjungang-ro, Gangseo-gu, Seoul, 07789, Replublic of Korea
R&D Center: Suite 6F, Genexine ProGen Bio Innovation Park, 172, Magokjungang-ro, Gangseo-gu, Seoul, 07789, Replublic of Korea
Copyright © ImmuneOncia. All Rights Reserved. DESIGNED BY DESIGNPIXEL